 BASEL, Switzerland and NEW YORK, Jan. 26, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV and Pfizer Inc. NYSE: PFE today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in women with endometriosis reported clinically meaningful reductions in dysmenorrhea menstrual pain and non-menstrual pelvic pain over one year 52 weeks with minimal and stable bone mineral density loss. The data are consistent with the efficacy and safety profile observed through 24 weeks in the Phase 3 SPIRIT 1 and SPIRIT 2 studies. These results will be included in the New Drug Application to the U.S. Food and Drug Administration for relugolix combination tablet for the treatment of women with endometriosis, anticipated to be submitted in the first half of 2021. 